Drugs / 89Zr-GSK2398852
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03417830 | Apr → Jul 2018 | amyloidosis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-GSK2398852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03417830 ↗ |
| Modality | Monoclonal antibody | “89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)” NCT03417830 ↗ |
| Route | Intravenous | “by the IV route” NCT03417830 ↗ |